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Abstract
Background: Neoplastic cells increase glycolysis in order to produce anabolic precursors and
energy within the hypoxic environment of a tumor. Ras signaling is activated in several cancers and
has been found to regulate metabolism by enhancing glycolytic flux to lactate. We examined the
effects of sequential immortalization and H-RasV12-transformation of human bronchial epithelial
cells on the anabolic fate of fully-labeled 13C-glucose-derived carbons using two-dimensional total
correlated spectroscopic analysis-nuclear magnetic resonance spectroscopy (2D TOCSY-NMR).
Results: We found that the introduction of activated H-RasV12 into immortalized human bronchial
epithelial cells unexpectedly increased tricarboxylic acid cycle activity as measured by the direct
conversion of 13C-glucose carbons into the anabolic substrates glutamate/glutamine, aspartate and
uridine. We then observed that immortalization and H-RasV12-transformation of bronchial
epithelial cells caused a stepwise increase in oxygen consumption, a global measure of electron
transport chain activity. Importantly, ectopic expression of H-RasV12 sensitized immortalized cells
to the ATP-depleting and cytotoxic effects of electron transport perturbation using the complex I
inhibitor rotenone.
Conclusion:  Taken together, these data indicate that the oncoprotein H-RasV12  increases
mitochondrial metabolism and provide new rationale for the targeting of the tricarboxylic acid
cycle and electron transport chain as anti-neoplastic strategies.
Background
Biosynthesis of proteins, nucleic acids, lipids and complex
carbohydrates requires coupling to the hydrolysis of nucl-
eoside triphosphates (ATP and GTP in protein biosynthe-
sis, CTP and UTP in lipid and carbohydrate biosynthesis),
as well as the incorporation of carbon and nitrogen from
metabolic precursors. Maintaining Na+/K+ ion gradients
and other ion gradients for transport consumes a large
fraction of the ATP generated in resting (G0/G1) cells, and
activating macromolecule biosynthesis in preparation for
cell division requires the production of additional ATP
equivalents. This need can be met under aerobic condi-
tions by increasing the flux of acetyl coenzyme A into the
tricarboxylic acid cycle (and via anaplerotic reactions to
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replenish carbon used for biosynthesis) derived from glu-
cose, amino acid and fatty acid oxidation. However, can-
cer cells have a tendency to increase the glycolytic flux
even under aerobic conditions, and secrete a large fraction
of the glucose carbons as lactate [1-7]. This implies a
bypass of oxidative phosphorylation, such that glycolysis
alone accounts for a substantial fraction of the ATP gener-
ation. This enhanced aerobic glycolysis is known as the
Warburg effect [8,9]. However, the precise mix of fuels
that drive cancer and normal epithelial cells is controver-
sial, and may well be dependent on cell type and the
growth conditions [3,10].
The Ras family of GTPases (H-, K- and N-Ras) function to
transduce signals from receptor tyrosine kinases (e.g. epi-
dermal growth factor receptor) that promote cell survival
and proliferation [11]. Activating mutations of the Ras
GTPases that cause insensitivity to inhibitory GTPase-acti-
vating proteins are among the most common genetic
alterations detected in human cancers [11]. Given the cen-
tral signaling role of Ras in cell proliferation and tumori-
genesis, it is not surprising that these oncoproteins also
mediate neoplastic metabolism. Ectopic expression of
oncogenic Ras in immortalized cells has been found to: (i)
increase glucose uptake and lactate production; (ii)
increase ribose-5-phosphate, a glucose-derived anabolic
precursor of DNA and RNA; and (iii) increase sensitivity
to the glycolytic inhibitors, 2-deoxyglucose and oxamate
[12-14]. However normal, non-immortalized human
bronchial epithelial cells supplemented with growth fac-
tors were recently observed to consume glucose and
secrete lactate at a similar rate as RasV12-transformed
human bronchial epithelial cells [15]. Accordingly, the
precise downstream metabolic effects of Ras signaling
within the setting of immortalized cells and in compari-
son to matched primary cells have not been well estab-
lished.
By monitoring the flow of 13C from fully labeled glucose
into metabolites, it is possible to determine the major
pathways that are influenced by immortalization and
transformation, including the activity of glycolysis, the
oxidative and non-oxidative pentose phosphate path-
ways, the tricarboxylic acid cycle and pyrimidine biosyn-
thesis. Herein, we report that the introduction of
oncogenic H-RasV12 into immortalized bronchial epithe-
lial cells increases the conversion of 13C from labeled glu-
cose into several shunt products of the tricarboxylic acid
cycle. Furthermore, we find that H-RasV12 increases oxygen
consumption and sensitizes the immortalized cells to
electron transport chain disruption. Importantly, the
observed increase in mitochondrial metabolism caused
by H-RasV12 may prove useful for the development of
agents that selectively disrupt the metabolism of neoplas-
tic cells.
Results
Glucose consumption and lactate secretion by normal, hT/
LT-immortalized and H-RasV12-transformed human 
bronchial epithelial cells
In order to examine the metabolic effects of mutant Ras in
cells relevant to human cancer, we obtained normal
human bronchial epithelial (NHBE) cells that had been
sequentially immortalized and transformed using the tel-
omerase catalytic subunit (hT), SV40 large T antigen (LT)
and an oncogenic allele of ras (H-RasV12) [16]. We con-
firmed that the normal human bronchial epithelial
(NHBE) cells had been stably transfected with the telom-
erase catalytic subunit (hT), SV40 large T antigen (LT) +/-
oncogenic H-RasV12 by Western blot analysis (Figure 1A
and 1B) [16]. The hT/LT cells are immortalized as they
have undergone >100 doublings and the hT/LT/Ras cells
are transformed as indicated by their capacity for anchor-
age-independent growth in soft agar and athymic mice
[16]. We found that the hT/LT and hT/LT/Ras cells prolif-
erate at a similar rate which is approximately 1.5x that of
primary NHBE cells (with growth factor stimulation) (Fig-
ure 1C). We also examined the size of each cell type and
found that the immortalized and ras-transformed bron-
chial epithelial cells were relatively smaller than the pri-
mary epithelial cells (NHBE: 1099 ± 82 μm3; hT/LT: 433
± 43 μm3; hT/LT/ras: 711 ± 56 μm3). We examined the rel-
ative glucose consumption and lactate secretion by these
three cell types over 72 hours and found that both the nor-
mal and the H-RasV12-transformed bronchial epithelial
cells consumed more glucose and secreted more lactate
than the immortalized cells during this time period as has
been previously reported (Figure 1D and 1E) (glucose
consumed: hT/LT vs. NHBE or hT/LT/Ras at 48 and 72
hours p < 0.05 ; lactate secreted: hT/LT vs. NHBE or hT/LT/
Ras at 24, 48 and 72 hours, p < 0.005) [15]. These results
confirm that H-RasV12 expression increases lactate secre-
tion in immortalized cells but indicate that high lactate
secretion may itself not be a distinct characteristic of neo-
plastic transformation since the primary cells also secrete
increased lactate. The high production of lactate relative to
glucose consumption in the primary, immortalized and
transformed epithelial cells indicates that lactate is being
produced from additional carbon sources such as pyru-
vate, glutamine and intracellular stores of glycogen.
Intracellular pyrimidine and purine ribose synthesis from 
glucose are similar in primary, immortalized and 
transformed bronchial epithelial cells
Two-dimensional nuclear magnetic resonance spectros-
copy (2D NMR) can be used to analyze the conversion of
glucose carbons into soluble intracellular metabolites of
anabolic pathways [17,18]. We cultivated NHBE, hT/LT
and hT/LT/Ras cells in medium containing 1 gm/L [U-
13C]-1,2,3,4,5,6-glucose and, after two population dou-
blings, extracted the cells with 10% trichloroacetic acidMolecular Cancer 2007, 6:77 http://www.molecular-cancer.com/content/6/1/77
Page 3 of 14
(page number not for citation purposes)
Proliferation, glucose consumption and lactate secretion by NHBE, hT/LT immortalized and hT/LT/Ras-transformed cells Figure 1
Proliferation, glucose consumption and lactate secretion by NHBE, hT/LT immortalized and hT/LT/Ras-trans-
formed cells. a. Protein extracted from normal human bronchial epithelial cells (NHBE), NHBE cells transduced with telom-
erase and large T antigen (hT/LT) and subsequently with H-rasV12 (hT/LT/Ras) was resolved on a 4–20% gradient gel, 
transferred to a PVDF membrane and expression of human telomerase (hTERT), SV40 large T antigen (LT), H-Ras and α-tubu-
lin was examined by Western blot analysis. b. Protein expression in NHBE, hT/LT and hT/LT/Ras cells by Western blot was 
quantified by densitometric analyses and expressed as percentage of control (α-tubulin). c. Primary, immortalized and H-
RasV12-transformed bronchial epithelial cells were cultured in growth media and enumerated after the indicated time periods. 
d. Unconsumed glucose remaining in the media was measured after 24, 48 and 72 hrs expressed as the (calculated) consumed 
glucose. e. Lactate secreted into the media by the cells was measured after 24, 48 and 72 hrs. d. Data are expressed as the 
mean ± SD of four experiments (b, c) and five experiments (d, e).
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and dissolved the lyophilized extract in 100% D2O. We
minimized the time required for the cell harvest and
washing to <20 minutes in order to ensure that subse-
quent analyses closely reflected the metabolic state
present during exponential growth. We recorded the NMR
spectra at 14.1 T with a spin lock field strength of 9 kHz
for 50 ms, using a cold probe under standardized condi-
tions of acquisition. 13C isotopomers were quantified by
indirect detection of protons in the 2D total correlated
spectroscopic analysis (TOCSY) NMR spectra. Figure 2
shows the region of the TOCSY spectra captured from
NHBE, hT/LT and hT/LT/Ras cells that includes both the
pyrimidine and purine riboses. These 12C-glucose-derived
molecules reveal a faint single cross peak for unlabeled
metabolites (center of dashed boxes), surrounded by four
satellite cross peaks that reflect the 13C-labeled molecules
(dashed box; Figure 2). The cross peak patterns near 6.2/
4.8 ppm correspond to ribose in purine nucleotides
(mainly ATP and ADP), and the cross peaks at 6/4.4 ppm
correspond to the pyrimidine nucleotide ribose (mainly
UTP and UDP). We observed only two species of the pyri-
midine and purine riboses present, the first in which all
carbons are 12C (central cross peak) and the second in
which all carbons are 13C (outer four cross peaks; Figure
2). These two pools derived from different carbon sources
and the fully labeled metabolites have been synthesized
directly from the 13C glucose supplied in the medium. The
high level of 13C-enrichment implies that there is consid-
erable de novo nucleotide biosynthesis in all three prolifer-
ating cell populations but that the immortalized and H-
RasV12-transformed bronchial epithelial cells exhibited
minimally increased activity compared with the untrans-
formed cells.
Increased conversion of glutamate/glutamine from glucose 
by Ras-transformed cells
Although glutamate and glutamine are non-essential
amino acids, there is considerable de novo biosynthesis, as
shown by the isotope incorporation. Figure 3 shows
regions of the TOCSY spectra that include the C2H pro-
tons interacting with the C3H and C4H protons of free
Glu, and in reduced glutathione. The pattern of the satel-
lite peaks is more complex than for the ribose described
above. In addition to the fully unlabeled molecules, there
are also all possible isotopomers, corresponding to singly,
doubly and triply labeled versions of the amino acids. Fur-
thermore, the relative intensities of these isotopomers are
unequal, which demonstrates the relative importance of
different pathways that lead to labeled glutamate and
glutamine (Figure 3). Unexpectedly, we observed a
marked increase in 13C-enrichment of the glutamate/
glutamine enrichment with H-RasV12-transformation
(compare hT/LT to hT/LT/Ras; ND = not detectable; Figure
3). Glutamate becomes labeled by transamination of 2-
oxoglutarate produced within the mitochondria. 13C can
enter into citrate either in 2-carbon steps by pyruvate
dehydrogenase (PDH) or as three carbons via the ana-
plerotic carboxylation of pyruvate. These two routes pro-
duce different label pattems in 2-oxoglutarate and the
specific labeling pattern indicates that both the PDH and
pyruvate carboxylase entry points are active. The observa-
tion that the introduction of H-RasV12 increases their rela-
tive 13C-enrichment provides substantial direct evidence
for the high activity of mitochondrial metabolism in H-
RasV12-transformed bronchial epithelial cells.
Increased 13C-glucose derived aspartate and uridine in 
Ras-transformed cells
TCA cycle intermediates may be used for biosynthesis in
order to satisfy the higher demand for nucleotides in
dividing cells. In Figure 4, the cross peak centered at 4.3/
3.1 ppm corresponds to the unlabeled aspartate which is
surrounded by the cross peaks of 13C-labeled aspartate
(dashed boxes). We observed a stepwise increase in aspar-
tate 13C-enrichment with sequential immortalization and
transformation of the normal human bronchial epithelial
cells (compare NHBE to hT/LT to hT/LT/Ras; Figure 4).
Like glutamate, aspartate is a product of an intermediate
in the tricarboxylic acid cycle (via the transamination of
oxaloacetate) and these data also indicate that introduc-
tion of activated H-RasV12 increases the activity of the tri-
carboxylic acid cycle. Furthermore, labeled aspartate
enters pyrimidine nucleotide biosynthesis. In Figure 5, the
cross peak pattern centered at 8/5.95 ppm corresponds to
the H6,H5 ring protons of uridine (UTP and UDP). The
satellite pattern shows a mixture of isotopomers, includ-
ing unlabeled, two singly labeled and a doubly labeled
variant (Figure 5). The C6 and C5 of uridine derive from
the α and β carbons of aspartate, respectively, which is
obtained by transamination of OAA. Although most steps
in pyrimidine biosynthesis are cytoplasmic, one step, cat-
alyzed by orotate dehydrogenase, occurs within the mito-
chondrial matrix, and requires the availability of
mitochondrial NAD+. The two singly labeled Asp and uri-
dine rings most probably arise from the incorporation of
label via PDH activity, followed by scrambling at the suc-
cinate step. These 13C enrichment data strongly indicate
that the TCA cycle is fully active in these cells.
hT/LT/Ras-transformed cells consume high oxygen and are 
especially sensitive to anoxia
Based on the relative increased flux of glucose into the tri-
carboxylic acid cycle, we speculated that hT/LT/Ras-trans-
formed bronchial epithelial cells may be more reliant on
electron transport than primary or immortalized bron-
chial epithelial cells. We measured basal oxygen con-
sumption and found that the introduction of RasV12
caused an increase in oxygen consumption relative to the
immortalized cells (Figure 6A). We then exposed the three
cell types to atmospheric oxygen or 0% oxygen in the pres-Molecular Cancer 2007, 6:77 http://www.molecular-cancer.com/content/6/1/77
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NMR-based isotopomer analysis of intracellular pyrimidine and purine ribose synthesis from glucose Figure 2
NMR-based isotopomer analysis of intracellular pyrimidine and purine ribose synthesis from glucose. The 
regions of the 2D TOCSY spectra captured from NHBE, hT/LT and hT/LT/Ras cells including both the pyrimidine and purine 
riboses were analyzed for relative 13C enrichment. The regions of the spectra showing the cross peaks of the nucleotide ribose 
moieties (H1'-H2' interaction) are shown.
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NMR-based isotopomer analysis of intracellular glutamate/glutamine synthesis from glucose Figure 3
NMR-based isotopomer analysis of intracellular glutamate/glutamine synthesis from glucose. The regions of 2D 
TOCSY spectra obtained from NHBE, hT/LT and hT/LT/Ras cells specific for the combined glutamate/glutamine, were analyzed 
for relative 13C enrichment. Spectra from NHBE, hT/LT and hT/LT/Ras cells are shown. 13C isotopomers were quantified by 
indirect detection of protons in the 2D TOCSY NMR spectrum and % 13C-enrichment is indicated adjacent to the cross peaks.
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NMR-based isotopomer analysis of intracellular aspartate synthesis from glucose Figure 4
NMR-based isotopomer analysis of intracellular aspartate synthesis from glucose. The regions of 2D TOCSY spec-
tra obtained from NHBE, hT/LT and hT/LT/Ras cells specific for aspartate were analyzed for relative 13C enrichment. Spectra 
from NHBE, hT/LT and hT/LT/Ras cells are shown. 13C isotopomers were quantified by indirect detection of protons in the 2D 
TOCSY NMR spectrum and % 13C-enrichment is indicated adjacent to the cross peaks.
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NMR-based isotopomer analysis of intracellular uridine synthesis from glucose Figure 5
NMR-based isotopomer analysis of intracellular uridine synthesis from glucose. The region of the spectra showing 
the cross peaks of the uridine bases (H6-H5) of NHBE, hT/LT and hT/LT/Ras cells are shown. 13C isotopomers were quantified 
by indirect detection of protons in the 2D TOCSY NMR spectrum and % 13C-enrichment is indicated adjacent to the cross 
peaks.
13C- Uri 23±2%
13C-Uri16±2%
13C- Uri24.5±2%
NHBE
hT/LT/Ras
hT/LTMolecular Cancer 2007, 6:77 http://www.molecular-cancer.com/content/6/1/77
Page 9 of 14
(page number not for citation purposes)
ence and absence of the complex I inhibitor, rotenone,
and, after 24 hours, measured intracellular ATP and cell
death. We found that the steady-state intracellular concen-
tration of ATP was reduced by rotenone to a greater extent
in the H-RasV12-transformed cells than in the primary and
immortalized cells (hT/LT/Ras vs. either NHBE or hT/LT, p
< 0.05) but that anoxia similarly affected the three cell
types (Figure 6B). The increased depletion of ATP by
Ras-transformed cells demonstrate increased dependence on mitochondrial respiration Figure 6
Ras-transformed cells demonstrate increased dependence on mitochondrial respiration. a. Oxygen consumption 
was measured using 5 × 106 primary (NHBE), immortalized (hT/LT) and Ras-transformed (hT/LT/Ras) bronchial epithelial cells 
in normoxia (21% oxygen) with a Clark type polarographic electrode. b. 5 × 105 primary bronchial epithelial cells (NHBE), 
immortalized (hT/LT) and transformed (hT/LT/Ras) cells were cultured in normoxia or anoxia +/- 10 μM rotenone for 24 h. 
The cells were washed X1, lysed and ATP was measured using a bioluminescent assay and values expressed as % of control. 
Cells in normoxia without rotenone were used as the control (ATP amounts of controls: NHBE 0.707 ± 0.018, hT/LT 0.734 ± 
0.07, hT/LT/Ras 0.7 ± 0.038 pmol per μg protein). c. 5 × 105 NHBE, hT/LT and hT/LT/Ras cells were cultured in normoxia or 
anoxia with or without rotenone for 24 hrs. Viable and non-viable cells were enumerated by Trypan blue exclusion using a 
hemacytometer.
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rotenone (in normoxic or anoxic conditions) was mir-
rored by increased cell death in the RasV12-transformed
cells (Figure 6C). Taken together, these data suggest that
activation of Ras signaling may cause an increased reli-
ance on the electron transport chain, a process that is
tightly coupled to the observed high tricarboxylic acid
cycle activity through the oxidation of NADH.
Discussion
The high enrichment of 13C-glucose-derived carbons into
glutamate/glutamine, aspartate and uridine in the H-
RasV12-transformed bronchial epithelial cells provides
unambiguous evidence that the tricarboxylic acid cycle is
highly active in these cells. That we observed increased
pooling of the 13C-glucose-derived products from the tri-
carboxylic acid cycle in the hT/LT/Ras-transformed bron-
chial epithelial cells suggests either that H-RasV12 causes
increased synthesis or decreased utilization of these ana-
bolic precursors. The NHBE, hT/LT and hT/LT/Ras cells
were allowed to double twice prior to extraction and NMR
analysis, and we thus anticipate that the relative anabolic
utilization of these precursors is not decreased by H-
RasV12. Coupled to the observations that oxygen con-
sumption is increased by H-RasV12 and that the H-RasV12-
transformed cells are especially sensitive to electron trans-
port perturbation by rotenone, the observed increase in
13C-enrichment of the glutamate/glutamine, aspartate
and uridine supports an increased activity of the tricarbo-
xylic acid cycle rather than decreased utilization of the
detected anabolic substrates.
The increased 13C-enrichment of glutamate/glutamine
and aspartate from glucose indicate increased TCA activ-
ity. The high glycolytic flux in these cells requires a means
of regenerating cytoplasmic NAD+. The fermentation of
pyruvate to lactate, followed by secretion of lactate into
the medium, can sustain only that part of glycolytic flux
that results in lactate production. Any additional glycoly-
sis that produces pyruvate that enters the TCA (for exam-
ple) needs a second means of regenerating NAD+. This
may stem from the activity of the aspartate/malate NADH
shuttle which previously has been found to be active in
neoplastic cells [19]. Mitochondrial and cytoplasmic
aspartate aminotransferases produce aspartate and gluta-
mate from oxaloacetate and α-ketoglutarate respectively
and are activated early in carcinogen-induced transforma-
tion in vivo [20]. Furthermore, the concentration of aspar-
tate and glutamate are increased in human colon and
gastric adenocarcinomas relative to matched normal tis-
sues [21]. The aspartate/malate shuttle functions to trans-
fer electrons via NADH produced from glycolysis into the
mitochondria for electron transport. Given that activated
H-RasV12 increases oxygen consumption and confers sen-
sitivity to electron transport perturbation, we speculate
that flux through this NADH shuttle may be increased by
oncogenic Ras and future studies will address this hypoth-
esis.
Several genetic alterations of cancer cause induction of
cellular proliferation through the epidermal growth factor
receptor (EGFR)-Ras-Raf-mitogen activated protein
kinase/extracellular signal-regulated kinase (MAPK/ERK;
MEK)-ERK-MAPK pathway, including EGFR amplifica-
tions (colorectal, pancreatic and lung cancers) and muta-
tions (lung adenocarcinomas and glioblastoma), and
activating mutations of Ras (pancreatic, papillary thyroid,
colon and lung cancers) and Raf (melanoma, papillary
thyroid and colon cancers) [11]. In this study, we have
found that activation of this signaling cascade through
ectopic expression of H-RasV12  in hT/LT-immortalized
bronchial epithelial cells causes an increase in the enrich-
ment of 13C-carbons from glucose into key anabolic pre-
cursors produced from tricarboxylic acid cycle
intermediates. Based on these observations, we predict
that downstream signaling effectors of the EGFR-Ras-Raf-
MEK-ERK-MAPK pathway cause activation of key rate-lim-
iting anabolic enzymes required for increased production
of these precursors. Furthermore, we postulate that the
metabolic rationale for increased pooling of these precur-
sors (i.e. glutamate and aspartate) in H-RasV12-trans-
formed proliferating cells may be related to the need for a
ready supply of substrates for the production of amino
acids since these precursors are required for the de novo
synthesis of several amino acids (i.e. glutamine, proline,
arginine, asparagine, methionine, lysine and threonine).
In support of this hypothesis, recent studies have demon-
strated that Ras/ERK signaling promotes translation initi-
ation by facilitating assembly of the preinitiation complex
[22]. Accordingly, increasing the availability of anabolic
substrates for the translational machinery may prove to be
a key metabolic event activated by oncogenic Ras.
Recent studies by Chen et al. have found that metastatic
breast cancer cells utilize aerobic glycolysis, coupled with
the tricarboxylic acid cycle and oxidative phosphorylation
to generate ATP needed for cellular proliferation [23].
They conducted proteomic analyses of breast cancer cells
isolated from a stage IV breast cancer patient before and
after metastatic spread to the brain in athymic mice and
observed a marked increase in the expression of proteins
involved not only in glycolysis but also in the tricarboxylic
acid cycle, including aconitate hydratase, isocitrate dehy-
drogenase and mitochondrial malate dehydrogenase, and
in oxidative phosphorylation, including cytochrome c
oxidase subunits, NADH-ubiquinone oxidoreductases
and ATP synthase chains. Ras is over-expressed in the
majority of breast adenocarcinomas examined [24-26]
and the observed high protein expression of tricarboxylic
acid cycle enzymes provides further support for the con-
clusion that the activities of the tricarboxylic acid cycleMolecular Cancer 2007, 6:77 http://www.molecular-cancer.com/content/6/1/77
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and electron transport chain are increased as a result of H-
RasV12-transformation.
Conclusion
Pharmacologic disruption of glycolysis is currently under
development as an anti-neoplastic strategy due to the
observations that tumor cells metabolize glucose rapidly
and are especially sensitive to glucose deprivation [6]. 3-
Bromopyruvate and 2-deoxyglucose are two compounds
that inhibit the first irreversible enzyme of glycolysis, hex-
okinase, and suppress tumor growth in vivo [27-29]. In
this study, we provide evidence for increased tricarboxylic
acid cycle activity, oxygen consumption and energetic reli-
ance on electron transport in H-RasV12-transformed cells
relative to matched, normal and immortalized cells. Based
on these observations, we conclude that inhibition of
mitochondrial metabolism may cause selective anti-neo-
plastic effects. It is noteworthy that several known cyto-
toxic agents function by targeting the mitochondria,
including arsenite, lonidamine and betulinic acid [30]. In
future studies, we will determine the precise downstream
Ras effector enzymes that regulate this metabolic shift in
order to develop highly targeted anti-metabolites as
chemotherapeutic agents.
Methods
Cell lines and cell culture
Normal human bronchial epithelial (NHBE) cells were
obtained from Cambrex (Walkersville, MD) and NHBE
cells expressing telomerase and SV40 large T antigen (hT/
LT) and activated Ras (hT/LT/Ras) were gifts from Dr. B. J.
Rollins, Dana Farber Cancer Institute. All experiments
with NHBE cells were conducted between 4 and 6 pas-
sages. NHBE, hT/LT and hT/LT/Ras cells were grown in
media containing 1 gm/L (5.5 mM) glucose and formu-
lated with bovine pituitary extract, recombinant human
epidermal growth factor, hydrocortisone, insulin, epine-
phrine, tri-iodothyronine, transferrin, gentamicin,
amphotericin B and retinoic acid (BEGM with Sin-
gleQuots, Cambrex, Walkersville, MD). All cells were
maintained at 37°C in 5% CO2. For some experiments,
NHBE, hT/LT and hT/LT/Ras cells were grown in 0% oxy-
gen (and 5% CO2) in a modular incubator chamber at
37°C (Billups-Rothenberg, Del Mar, CA). For certain
other experiments, NHBE, hT/LT and hT/LT/Ras cells were
treated with 10 μM rotenone (Sigma, St. Louis, MO) for
24 hours. The cells were enumerated by direct visualiza-
tion using light microscopy. Sizes of NHBE, hT/LT and
hT/LT/Ras cells were determined using Imagestream and
IDEAS software (both from Amnis, Seattle, WA).
For NMR experiments, after cells reached 25% confluence,
the media was changed to glucose-free Dulbecco's modi-
fied Eagle medium (DMEM, Invitrogen, Grand Island,
NY) supplemented with SingleQuots (Cambrex) as above
and also with 13C labeled glucose (5.5 mM) from a sterile
20% stock solution of [U-13C6]-glucose (98% 13C) (Cam-
bridge Isotopes Laboratories, Andover, MA) in phos-
phate-buffered saline.
Protein extraction and Western blotting
Cells were treated with 0.25% trypsin-EDTA, washed in
PBS, and lysed in 2x RIPA buffer. Protein samples were
resolved on a 4–20% gradient SDS-PAGE gel and trans-
ferred to a PVDF membrane. Membranes were blocked in
TBS-Tween 20 (1%) containing 5% milk. Either rabbit
anti-hTERT (1:250, Rockland Immunochemicals, Gil-
bertsville, PA), mouse anti-β-actin (1:5000, Sigma, St.
Louis, MO), rabbit anti-H-Ras (1:1000, Santa Cruz Bio-
technology, Santa Cruz, CA) or mouse anti-SV40 large T-
antigen antibody (1:1000, Oncogene/Calbiochem, San
Diego, CA) were re-suspended in 10 ml of TBS-Tween 20
(5% milk) and incubated with the membrane for 1 hour.
Secondary antibodies were goat anti-rabbit or anti-mouse
HRP conjugated (1:8000, Pierce Biotechnology, Rockford,
IL). All Western blotting experiments were repeated for a
total of 4 experiments.
Scanned images were quantified by densitometric analy-
ses using Quantiscan software Version 3.0 (Biosoft,
United Kingdom). Values obtained were normalized to α-
tubulin) (as a control) and expressed in densitometric
units as a percentage of the control. All values represent
the mean ± SD of 4 independent experiments.
Lactate and glucose measurements
Lactate concentrations in the media were measured using
a lactate oxidase-based assay read at 540 nm (Trinity,
Wicklow, Ireland). Glucose concentrations were meas-
ured using a hexokinase-glucose-6-phosphate dehydroge-
nase enzymatic assay read at 340 nm (Sigma, St. Louis,
MO). All data are expressed as the mean ± SD of five
experiments. Statistical significance was assessed by the
unpaired two-tail t-test.
Metabolite extraction
Cells grown in the presence of 13C-labeled glucose were
harvested after two population doublings by trypsiniza-
tion with 0.25% trypsin-EDTA for 60 seconds at 37°C in
5% CO2 and low speed centrifugation. The cells were
counted by direct visualization using light microscopy
and equal numbers of cells were spun down, washed twice
with ice-cold PBS followed by low speed centrifugation
(1000 rpm) at 4°C to remove adhering medium, and then
flash frozen in liquid N2. The cold pellet was extracted
with 10% ice-cold TCA (twice), followed by lyophiliza-
tion as previously described [17,18]. Dry cell extract was
redissolved in 0.35 ml D2O with 142 μM DSS (2, 2-dime-
thyl-2-silapentane-5-sulfonate sodium salt) as both aMolecular Cancer 2007, 6:77 http://www.molecular-cancer.com/content/6/1/77
Page 12 of 14
(page number not for citation purposes)
chemical shift reference and as a concentration standard
and loaded into a 5 mm Shigemi tube.
Nuclear Magnetic Resonance
All NMR spectra were recorded at 14.1 T on Varian Inova
NMR spectrometer at 20°C using a 90° excitation pulse.
1D spectra were recorded using an acquisition time of 2
seconds and a relaxation delay of 3 seconds during with
the residual HOD signal was suppressed using a weak
transmitter pulse (ca. 20 Hz B1 field). For analyzing the
cellular extracts and determining the positional enrich-
ment with 13C we used 2D experiments (TOCSY and
HSQC), and analyzing the satellite peaks in the TOCSY as
described in detail [31,32]. TOCSY experiments were
recorded with a 6000 Hz spectral width both dimensions,
0.341 s acquisition time in t2 and 0.05 s in t1, a recycle
time of 2 s, a 50 ms isotropic mixing time, and a B1 field
strength of 8 kHz generated with MLEV-17. The data
tables were zero filled to 8192 by 2048 complex points,
apodized using an unshifted Gaussian function and 0.5
Hz line broadening exponential in both dimensions prior
to double fourier transformation.
Metabolites were assigned based on their 1H and 13C
chemical shifts, and TOCSY connectivity pat-
terns[17,33,34], and compared with our in-house data
base of standards recorded under identical conditions
[31]. Metabolite concentrations were determined by com-
paring the area of assigned resonances to that of the DSS
methyl group (9 protons) according to Eq (1):
c(S) = c(DSS).A(s)n(S)/9A(DSS) (1)
Where c(S) is the concentration of the desired solute,
c(DSS) is the concentration of the DSS standard, A(s),
A(DSS) are the areas of the solution and DSS resonances,
and n is the number of protons in the solute peak (e.g. 3
for lactate methyl protons). With the recycle time used,
the degree of saturation was small under the conditions of
the experiments. Saturation factors were assessed by inde-
pendent measurements of the T1values using inversion
recovery, according to:
M(obs) = M(true) (1-exp-R1D) (2)
Where M(obs), M(true) are the observed and fully relaxed
magnetizations, R1 is the spin-lattice relaxation rate con-
stant and D is the recycle time.
Isotope enrichment from NMR
13C enrichment was determined from peak areas in 1D
spectra for well-resolved metabolites such as the lactate
methyl group. Peak areas of the satellite, A(13C), and cen-
tral, A(12C), resonances were determined by integration
after careful phasing and baseline flattening. The %13C
was then calculated according to Eq. (3):
F = 100A(13C)/[(A(13C)+A(12C)] (3)
For metabolites poorly resolved in 1D spectra, we used the
2D TOCSY method as previously described [31,32]. The
base-planes were carefully corrected, and cross peak vol-
umes were determined by volume integrated using
VNMR. This approach has been shown to provide very
accurate, and unbiased estimates of the 13C content. The
various isotopomer enrichments were calculated by
replacing the peak area with peak volumes in equation 3.
In these TOCSY experiments, the protons were partially
saturated owing to the shorter recycle time (2 s). Thus, the
actual peak volumes were corrected according to the dif-
ferential T1  values of protons attached to 13C or 12C
according to Eq. (2). Effective T1 values were determined
on standards recorded under the same solvent conditions
using the inversion recovery sequence.
Analytical precision was determined by replicate analysis
of symmetry related cross peaks, and on spectra trans-
formed using slightly different window functions. The
errors were then estimated with respect to the signal to
noise ratios of the peaks. The number of biological repli-
cates was 3.
Oxygen consumption
NHBE, hTLT and hT/LT/Ras cells in culture were detached,
washed × 1 with PBS and resuspended in complete BEGM
medium at 107cells/ml. Oxygen consumption was meas-
ured using 5 × 106 cells in 500 μL medium at 37°C using
a Clark-type polarographic electrode (Strathkelvin Mito-
cell MT 200, Motherwell, United Kingdom). A starting O2
concentration of 215 μM was assumed based on O2 solu-
bility at sea level at 37°C [35-37]. Experiments were
repeated for a total of five times. The data shown are the
results of a single representative experiment.
ATP measurements
5 × 105 NHBE, hTLT and hT/LT/Ras cells in culture for 24
hrs in normoxia (21% oxygen) or anoxia (0% oxygen) +/
- 10 μM rotenone were washed (while still adherent) with
cold PBS ×1. Passive lysis buffer (1X, Molecular Probes,
Invitrogen, Carlsbad, CA) was then added directly to the
plates and the cells immediately harvested by scraping.
The lysates were flash frozen (to -80°C) and thawed (to
37°C) once to accomplish complete lysis and then centri-
fuged (at 4°C) for 30 seconds to clear the lysates. Intracel-
lular ATP levels were determined using a bioluminescence
assay (Molecular Probes) utilizing recombinant firefly
luciferase and its substrate, D-luciferin and following
manufacturer's instructions. The luminescence was read
in a TD-20/20 luminometer (Turner Designs, Sunnyvale,Molecular Cancer 2007, 6:77 http://www.molecular-cancer.com/content/6/1/77
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CA) at 560 nm. The ATP values were calculated using an
ATP standard curve. The protein concentrations of the
lysates were estimated using the bicinchoninic acid (BCA)
assay (Pierce Biotechnology, Rockford, IL) and ATP was
expressed as pmol per μg protein. All data are expressed as
the mean ± s.d. of five experiments. Statistical significance
was assessed by the unpaired two-tail t-test.
Cell viability
5 × 105 NHBE, hTLT and hT/LT/Ras cells were plated in
normoxia or anoxia with or without 10 μM rotenone for
24 hrs, detached (with 0.25% Trypsin/EDTA) and
counted using a hemacytometer. Cell viability was
assessed by Trypan blue exclusion. Trypan blue solution
was prepared by combining 0.5 ml of Trypan blue (Sigma,
St Louis, MO) with 0.3 ml of PBS. Cells in suspension
were mixed 1:1 with Trypan blue solution and incubated
at room temperature for 5 min. The numbers of unstained
(viable), stained (dead) and total cells were counted in a
hemacytometer by two independent observers and the
percentage of viable cells calculated. The numbers of cells
counted in the hemacytometer were between 100–500
(1–5 × 106 cells/microliter). All data are expressed as the
mean ± s.d. of five experiments. Statistical significance
was assessed by the unpaired two-tail t-test.
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